company background image

Intuitive Surgical NasdaqGS:ISRG Stock Report

Last Price


Market Cap







03 Oct, 2022


Company Financials +
ISRG fundamental analysis
Snowflake Score
Future Growth3/6
Past Performance2/6
Financial Health6/6

ISRG Stock Overview

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally.

Intuitive Surgical Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Intuitive Surgical
Historical stock prices
Current Share PriceUS$193.36
52 Week HighUS$369.69
52 Week LowUS$184.94
1 Month Change-5.06%
3 Month Change-6.48%
1 Year Change-40.23%
3 Year Change10.16%
5 Year Change63.58%
Change since IPO9,534.55%

Recent News & Updates

Sep 30

Japanese regulatory agency clears Intuitive's single-port robotic surgical system

Medical device maker Intuitive Surgical (NASDAQ:ISRG) on Friday said Japan's health ministry had approved its da Vinci single-port surgical system for use in surgeries. The approval came from Japan's Ministry of Health, Labour and Welfare, and clears the system for use in general, thoracic, urologic, gynecological, and trans-oral head and neck surgeries, the company said in a statement. ISRG's da Vinci SP system provides surgeons with robotic-assisted multi-jointed arms designed for deep and narrow access to tissue in the body. The system also comes with a fully wristed 3D high-definition camera. Surgeons can control the arms and the camera from a console. ISRG makes the bulk of its sales from its da Vinci surgical systems. The company in July said procedures with the systems grew about 14% Y/Y for Q2, and reported revenue of $1.52B. Intuitive (ISRG) stock closed -1.7% at $189.06 on Thursday.

Sep 26
Returns On Capital At Intuitive Surgical (NASDAQ:ISRG) Paint A Concerning Picture

Returns On Capital At Intuitive Surgical (NASDAQ:ISRG) Paint A Concerning Picture

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...

Sep 23

Intuitive Surgical: Fundamentally Fairly Valued, Technically Risky (Technical Analysis)

Summary Intuitive Surgical bottomed on June 16 and has since rallied over 30% in a breakout attempt that finally failed and led the stock back down. The stock has been a strong leader in its industry and can quickly retrace in a favorable situation, but is now building up more weakness. With 69% performance, ISRG has recently corrected pairing the performance of its industry but mostly outperformed its references over the past 5 years. The stock has likely a relatively low upside potential until a sound base has formed, and could reach even lower lows, as the closest support level could soon be tested. Investment thesis Intuitive Surgical Inc. (ISRG) is a strong technology leader and has also been a long-term leader in terms of performance in its industry and sector. But the stock is suffering from a persistent downtrend since its ATH in December 2021, which has led the stock to lose 50% of its value. Although its capability to quickly retrace in a favorable market, the stock seems now heading towards the lows set in June 2022, and could even break under those levels, as it builds up significant weakness. If the June lows don't hold, the most likely support levels are seen at $181 and 170.50, with a short-term worst-case scenario around $161. If the stock manages to rebound in the near term, investors should watch out for its strongest overhead resistance, now set by its EMA50, its EMA100, and the ceiling of the trend channel. A quick look at the big picture After showing some relative strength during the past year, the healthcare sector in the US has recently plunged again into negative territory led by pharmaceutical retailers, specialty and generic drug manufacturers, and companies providing health information services. Companies in the medical distribution industry, as well as those providing healthcare plans and medical care facilities, could keep up better in the group. finviz finviz The iShares U.S. Medical Devices ETF (IHI) has substantially underperformed the broader Health Care Select Sector SPDR (XLV) since November 2021. The industry began to improve in July 2022 and showed some relative strength in August until mid-September, but has since lost momentum and has now fallen to the lows seen in June. The industry reference seems to struggle to overcome its long-term downtrend as it got rejected between its EMA100 and EMA200 and is now strongly negatively oriented, and priced under all its most important moving averages. Author, using TradingView Looking back even further, Intuitive Surgical has outperformed its main sector reference and could, for most of the time in the past 5 years, establish itself significantly better in its industry, but has recently strongly corrected, resulting in 69.04% performance over the analyzed time, slightly worse than the iShares U.S. Medical Devices ETF (IHI) and almost 30% less than the broader technology market. Author, using Where are we now? Since my last article Intuitive Surgical Faces More Challenges published on May 10, 2022, where I suggested the stock was fundamentally fairly priced and may be in an unfavorable technical situation, the stock has lost over 14% and bottomed only on June 16, while instantly forming a strong rebound that led the stock 31% higher until the beginning of August. The recent retracement is characterized by substantial increasing sell volume and relative weakness, as the stock got rejected on its EMA50 breakout attempt, and is now close to the lows seen in June. Author, using TradingView Although it's still early to determine if a significant new downtrend is forming or if this pullback is all part of the bottoming process, it's important to note that since topping in August at the overhead resistance formed by the trend-channel ceiling, the trading sessions were predominantly characterized by heavy sell-side volume, and more positive days could not convince in terms of volume. The stock is technically in a very unfavorable situation, and it's worth it to estimate what the most likely outcomes could be, to be able to adjust the contingency plan. What is coming next Despite the stock still seemingly fundamentally fairly priced, technically it seems to be more likely to continue its short-term downtrend, while I expect the stock to slowly improve its performance in its industry in the near term, reporting sporadic relative strength. The levels close to the June lows, will show if the stock is trying to form a sound base, from which it would start its next attempt to break out, or if new lows will be achieved. Author, using TradingView If the stock doesn't rebound on its support around $187, my projections suggest the most likely short-term price target be set at $181, $170.50, and successively at 160.60. While I qualify the upside potential at around $210-240, with possible catalysts coming up next, the company will report its Q3 results towards mid-October. Investors should closely observe the price action and how the stock behaves at the next support and resistance levels, and how an eventual attempt to break under its support is confirmed or rejected, by particularly observing the trading volume in both directions and the relative strength. The stock could continue by forming an extended downtrend and overcoming its low set on June 16, which would lead the stock to price levels not seen since the pandemic lows. If the stock instead rebounds, the next important resistance levels are set by its EMA50, the EMA100, and the ceiling of the trend channel. As the stock just made a gap down, I would put particular attention to the next sessions, and keep my stop-loss tight, to avoid being caught in a continuation of the downtrend. The bottom line Technical analysis is not an absolute instrument, but a way to increase investors' success probabilities and a tool allowing them to be oriented in whatever security. One would not drive towards an unknown destination without consulting a map or using a GPS. I believe the same should be true when making investment decisions. I consider techniques based on the Elliott Wave Theory, as well as likely outcomes based on Fibonacci's principles, by confirming the likelihood of an outcome contingent on time-based probabilities. The purpose of my technical analysis is to confirm or reject an entry point in the stock, by observing its sector and industry, and most of all its price action. I then analyze the situation of that stock and calculate likely outcomes based on the mentioned theories.

Aug 23

Intuitive Surgical: Raising The Red Flag On The Hospital Industry

Intuitive is a quality company with high recurring revenue and a flawless balance sheet. The main consumer of the company's products, however, is fundamentally flawed and will be exposed by the recession. It will get worse before it gets better for investors. You wouldn't expect a company that controls 80% of its market, which is expected to grow at a 10% CAGR for the next decade, to be down 35% YTD, yet Intuitive Surgical (ISRG) finds itself in this exact position. An abysmal quarter further amplified that major negative catalysts are beginning to take hold, forecasting more pain ahead. Competitive Edge Many know Intuitive as a surgical robotics company, we know it as an integrated ecosystem of health services. Despite having a 20-year technological head start, the company wanted to prepare for competitors to eat away at market share. And so, management took a page out of Apple's (AAPL) playbook to combat the issue: create other services to trap customers. J.P. Morgan Healthcare Conference Its education and data analytics apps have shown strong growth, helping hospitals become increasingly efficient at surgeries. These tools make it easier and cheaper to purchase more da Vinci systems or their new Ion platform, a great selling point for that product. Added features combined with regular maintenance costs have made Intuitive a recurring revenue powerhouse, accounting for 75% of revenues. J.P. Morgan Healthcare Conference Intuitive's sticky business model makes Johnson & Johnson's (JNJ) Ottova robot or Medtronic's (MDT) Hugo system irrelevant to them as existing consumers will likely continue to spend on their products because switching costs are too high. Both competitors also announced that pricing will be comparable to the da Vinci machines, meaning management can use their pricing power and reputation to win over surgeons. Having customer loyalty dramatically reduces the need for marketing expenditures, and with no debt on the balance sheet, gives Intuitive the flexibility to plow cash into R&D. Author, Stock Analysis In 2022, R&D as a % of Revenue is projected to reach an all-time high, a bullish sign as we know increased investments will translate to new revenue streams, helping the company distance itself from other players. But if their moat is this wide then it begs the question, what headwinds caused a dreary Q2 and a bleak outlook? For this, we must turn to Intuitive's only consumer: hospitals. Negative Catalysts Although the healthcare sector is often branded as recession-proof, healthcare equipment companies face downturns due to the poorly run privatized hospital industry. To better understand the problem, we need to examine the 2010s carefully. Medical innovation was at its peak with biotechs on the rise and Intuitive's new da Vinci Xi machine released in 2014, leading patients to want the highest standard of care via new-age, expensive treatments. To meet demand, hospitals big and small began taking on long-term debt to afford medicines and surgeries, an action encouraged by record-low interest rates ripe for abuse. Just look at Connecticut's hospital system. In FY 2011, medical facilities in Danbury, Hartford, Norwalk, and more were tripling debt into the billions only 3 years removed from the worst financial crisis in history. This robust appetite for debt only expanded through the decade, becoming the primary driver of growth. However, in today's macroeconomic backdrop, the financial leverage hospitals have been accumulating is finally being exposed. Rate hikes have led to a drastic slowdown in borrowing, and the massive amounts of debt on the balance sheet means more cash must flow towards paying things down. Whatever money is not being used to become more financially stable, is going towards inflated expenditures. Over the past year, medical supplies have increased by 20.6% along with drug expenses going up 36.9% leading 1/3 of hospitals to have negative margins. These ugly margins combined with massive amounts of debt leave minimal room for CapEx, including Intuitive's robotic machines. Hospitals aren't going to shell out $1.5M on a da Vinci system or $600K on an Ion platform and then spend $200k in annual maintenance and technology fees. We are seeing this problem unfold right in front of our eyes.

Jul 26
Estimating The Intrinsic Value Of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Estimating The Intrinsic Value Of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Does the July share price for Intuitive Surgical, Inc. ( NASDAQ:ISRG ) reflect what it's really worth? Today, we will...

Shareholder Returns

ISRGUS Medical EquipmentUS Market

Return vs Industry: ISRG underperformed the US Medical Equipment industry which returned -31.5% over the past year.

Return vs Market: ISRG underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is ISRG's price volatile compared to industry and market?
ISRG volatility
ISRG Average Weekly Movement5.0%
Medical Equipment Industry Average Movement8.5%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: ISRG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: ISRG's weekly volatility (5%) has been stable over the past year.

About the Company

19959,793Gary Guthart

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights.

Intuitive Surgical Fundamentals Summary

How do Intuitive Surgical's earnings and revenue compare to its market cap?
ISRG fundamental statistics
Market CapUS$69.05b
Earnings (TTM)US$1.43b
Revenue (TTM)US$5.96b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ISRG income statement (TTM)
Cost of RevenueUS$1.90b
Gross ProfitUS$4.07b
Other ExpensesUS$2.63b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Oct 18, 2022

Earnings per share (EPS)4.02
Gross Margin68.16%
Net Profit Margin24.05%
Debt/Equity Ratio0.0%

How did ISRG perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is ISRG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ISRG?

Other financial metrics that can be useful for relative valuation.

ISRG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue10.8x
Enterprise Value/EBITDA31.9x
PEG Ratio2.8x

Price to Earnings Ratio vs Peers

How does ISRG's PE Ratio compare to its peers?

ISRG PE Ratio vs Peers
The above table shows the PE ratio for ISRG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average44.5x
BDX Becton Dickinson
SYK Stryker
EW Edwards Lifesciences
BSX Boston Scientific
ISRG Intuitive Surgical

Price-To-Earnings vs Peers: ISRG is expensive based on its Price-To-Earnings Ratio (48.1x) compared to the peer average (44.5x).

Price to Earnings Ratio vs Industry

How does ISRG's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Earnings vs Industry: ISRG is expensive based on its Price-To-Earnings Ratio (48.1x) compared to the US Medical Equipment industry average (32.2x)

Price to Earnings Ratio vs Fair Ratio

What is ISRG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ISRG PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio48.1x
Fair PE Ratio45.8x

Price-To-Earnings vs Fair Ratio: ISRG is expensive based on its Price-To-Earnings Ratio (48.1x) compared to the estimated Fair Price-To-Earnings Ratio (45.8x).

Share Price vs Fair Value

What is the Fair Price of ISRG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ISRG ($193.36) is trading below our estimate of fair value ($277.93)

Significantly Below Fair Value: ISRG is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is Intuitive Surgical forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

Future Growth Score


Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ISRG's forecast earnings growth (17.3% per year) is above the savings rate (1.9%).

Earnings vs Market: ISRG's earnings (17.3% per year) are forecast to grow faster than the US market (14.8% per year).

High Growth Earnings: ISRG's earnings are forecast to grow, but not significantly.

Revenue vs Market: ISRG's revenue (11.5% per year) is forecast to grow faster than the US market (7.7% per year).

High Growth Revenue: ISRG's revenue (11.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ISRG's Return on Equity is forecast to be low in 3 years time (16.2%).

Discover growth companies

Past Performance

How has Intuitive Surgical performed over the past 5 years?

Past Performance Score


Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ISRG has high quality earnings.

Growing Profit Margin: ISRG's current net profit margins (24.1%) are lower than last year (31.4%).

Past Earnings Growth Analysis

Earnings Trend: ISRG's earnings have grown by 14.7% per year over the past 5 years.

Accelerating Growth: ISRG's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ISRG had negative earnings growth (-11.6%) over the past year, making it difficult to compare to the Medical Equipment industry average (-0.2%).

Return on Equity

High ROE: ISRG's Return on Equity (12%) is considered low.

Discover strong past performing companies

Financial Health

How is Intuitive Surgical's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: ISRG's short term assets ($6.3B) exceed its short term liabilities ($1.2B).

Long Term Liabilities: ISRG's short term assets ($6.3B) exceed its long term liabilities ($447.8M).

Debt to Equity History and Analysis

Debt Level: ISRG is debt free.

Reducing Debt: ISRG has not had any debt for past 5 years.

Debt Coverage: ISRG has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ISRG has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies


What is Intuitive Surgical current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Intuitive Surgical Dividend Yield vs Market
How does Intuitive Surgical dividend yield compare to the market?
SegmentDividend Yield
Company (Intuitive Surgical)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Medical Equipment)1.8%
Analyst forecast in 3 Years (Intuitive Surgical)0%

Notable Dividend: Unable to evaluate ISRG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ISRG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ISRG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ISRG's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ISRG has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Gary Guthart (56 yo)





Dr. Gary S. Guthart, Ph D., has been Chief Executive Officer of Intuitive Surgical, Inc. since January 1, 2010 and its President since July 12, 2007. Dr. Guthart served as the Chief Operating Officer at In...

CEO Compensation Analysis

Gary Guthart's Compensation vs Intuitive Surgical Earnings
How has Gary Guthart's remuneration changed compared to Intuitive Surgical's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$8mUS$846k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$6mUS$821k


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019US$6mUS$790k


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018US$6mUS$767k


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018n/an/a


Dec 31 2017US$5mUS$744k


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017n/an/a


Dec 31 2016US$5mUS$708k


Sep 30 2016n/an/a


Jun 30 2016n/an/a


Mar 31 2016n/an/a


Dec 31 2015US$4mUS$690k


Compensation vs Market: Gary's total compensation ($USD8.06M) is below average for companies of similar size in the US market ($USD13.04M).

Compensation vs Earnings: Gary's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

Leadership Team

Experienced Management: ISRG's management team is considered experienced (4 years average tenure).

Board Members

Experienced Board: ISRG's board of directors are considered experienced (6.8 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ISRG?
Owner TypeNumber of SharesOwnership Percentage
Private Companies00%
State or Government156,8260.04%
Individual Insiders1,589,4760.4%
General Public52,872,92714.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 52.96% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
The Vanguard Group, Inc.
BlackRock, Inc.
T. Rowe Price Group, Inc.
State Street Global Advisors, Inc.
Edgewood Management LLC
Capital Research and Management Company
AllianceBernstein L.P.
J.P. Morgan Asset Management, Inc.
Geode Capital Management, LLC
Fisher Asset Management, LLC
Walter Scott & Partners Limited
BNY Mellon Asset Management
Baillie Gifford & Co.
Northern Trust Global Investments
Polen Capital Management, LLC
Teachers Insurance and Annuity Association-College Retirement Equities Fund
Brown Advisory Incorporated
Jennison Associates LLC
American Century Investment Management Inc
Franklin Resources, Inc.
Norges Bank Investment Management
Eaton Vance Management
ClearBridge Investments, LLC
Legal & General Investment Management Limited

Company Information

Intuitive Surgical, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Intuitive Surgical, Inc.
  • Ticker: ISRG
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$69.051b
  • Shares outstanding: 357.11m
  • Website:

Number of Employees


  • Intuitive Surgical, Inc.
  • 1020 Kifer Road
  • Sunnyvale
  • California
  • 94086-5304
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ISRGNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2000
IUI1DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2000
0R29LSE (London Stock Exchange)YesCommon StockGBUSDJun 2000
ISRGWBAG (Wiener Boerse AG)YesCommon StockATEURJun 2000
ISRG *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJun 2000
IUI1ETLX (Eurotlx)YesCommon StockITEURJun 2000
I1SR34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 10 REPR 1 COMBRBRLJan 2020

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/03 00:00
End of Day Share Price2022/10/03 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.